First Time Loading...

ADC Therapeutics SA
NYSE:ADCT

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
NYSE:ADCT
Watchlist
Price: 4.5 USD 7.14% Market Closed
Updated: Mar 28, 2024

ROE
Return on Equity

806.2%
Current
-105%
Average
-29.6%
Industry
Positive for the last year
806.2%
Negative average
-105%
Better than average
Better than industry value

ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.

ROE
806.2%
=
Net Income
-240.1m
/
Equity
-29.8m

ROE Across Competitors

ROE Comparison
ADC Therapeutics SA Competitors

Country CH
Market Cap 371.4m USD
ROE
806%
Country US
Market Cap 319.7B USD
ROE
35%
Country US
Market Cap 153.2B USD
ROE
136%
Country US
Market Cap 108.4B USD
ROE
23%
Country US
Market Cap 105.1B USD
ROE
16%
Country US
Market Cap 91.4B USD
ROE
26%
Country AU
Market Cap 139.1B AUD
ROE
15%
Country US
Market Cap 43.1B USD
ROE
-28%
Country US
Market Cap 41.6B USD
ROE
-29%
Country US
Market Cap 31.2B USD
ROE
8%
Country KR
Market Cap 40.1T KRW
ROE
14%

ROE Distribution

ROE Distribution
Biotechnology Industry

Profitability Report

View the profitability report to see the full profitability analysis for ADC Therapeutics SA.

See Also

Discover More
What is Return on Equity?

ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.

ROE
806.2%
=
Net Income
-240.1m
/
Equity
-29.8m
What is the ROE of ADC Therapeutics SA?

Based on ADC Therapeutics SA's most recent financial statements, the company has ROE of 806.2%.